Treatment of relapsed multiple myeloma: Evidence-based recommendations.

Abstract

The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.

• Authors: Ceren Durer, Seren Durer, Sarah Lee, Rajshekhar Chakraborty, Mustafa Nadeem Malik, Abdul Rafae, Muhammad Abu Zar, Ahmad Kamal, Nathaniel Rosko, Christy Samaras, Jason Valent, Chakra Chaulagain, Faiz Anwer
• Journal: Blood reviews (Blood Rev) Vol. 39 Pg. 100616 (01 2020) ISSN: 1532-1681 [Electronic] England
• PMID: 31500848 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 Elsevier Ltd. All rights reserved.

Topics

• Evidence-Based Practice (methods)
• Humans
• Multiple Myeloma (therapy)
• Neoplasm Recurrence, Local